Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

NCT06082102 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Marginal Zone Lymphoma

Interventions

DRUG: Orelabrutinib
DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Rituximab

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.